Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU)

Bioorg Med Chem Lett. 2001 Sep 3;11(17):2225-8. doi: 10.1016/s0960-894x(01)00410-3.

Abstract

Stemming from work on a previous clinical candidate, loviride, and other alpha-APA derivatives, a new series of potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been synthesized. The ITU analogues, which contain a unique diarylated imidoyl thiourea, are very active in inhibiting both wild-type and clinically important mutant strains of HIV-1.

MeSH terms

  • Acetamides / chemistry
  • Acetamides / pharmacology
  • Acetophenones / pharmacology
  • Aniline Compounds / chemistry
  • Anti-HIV Agents / chemical synthesis
  • Anti-HIV Agents / chemistry*
  • Anti-HIV Agents / pharmacology*
  • Drug Design
  • Drug Evaluation, Preclinical
  • Drug Stability
  • HIV Reverse Transcriptase / antagonists & inhibitors*
  • HIV Reverse Transcriptase / drug effects
  • HIV Reverse Transcriptase / genetics
  • HIV-1 / drug effects
  • Imines / chemistry*
  • Imines / pharmacology*
  • Structure-Activity Relationship
  • Thiourea / analogs & derivatives
  • Thiourea / chemistry*
  • Thiourea / pharmacology*

Substances

  • Acetamides
  • Acetophenones
  • Aniline Compounds
  • Anti-HIV Agents
  • Imines
  • N'-(2-((2,6-dichlorophenyl)methyl)-1-iminoethyl)-N''-(4-cyanophenyl)thiourea
  • alpha-anilinophenylacetamide
  • loviride
  • HIV Reverse Transcriptase
  • Thiourea